Literature DB >> 27730453

Is it essential to use fiducial markers during cone-beam CT-based radiotherapy for prostate cancer patients?

Berna A Yildirim1, Cem Onal2, Yemliha Dolek1.   

Abstract

PURPOSE: To compare soft-tissue cone-beam computed tomography (CBCT-P) and fiducial marker (CBCT-FM)-based image guided radiotherapy in prostate cancer patients.
MATERIALS AND METHODS: Sixteen prostate cancer patients were treated with volumetric modulated arc therapy. Manual alignment using CBCT-P and CBCT-FM was performed for each patient. Couch shifts were calculated and compared between methods in the left-right (x), superior-inferior (y), and anterior-posterior (z) directions.
RESULTS: CBCT-P and CBCT-FM alignments were compared using 252 scans from the 16 patients. Mean displacement from zero was 2.4 ± 1.3, 1.7 ± 1.2, and 1.8 ± 1.1 mm for CBCT-P and 2.3 ± 1.3, 1.7 ± 1.1 and 1.8 ± 1.1 mm for CBCT-FM in the x, y and z directions, respectively. There was no difference in median displacement between CBCT-P and CBCT-FM; however, there was a significant positive correlation between CBCT-P- and CBCT-FM-based displacements in the x (r = 0.881; p < 0.001), y (r = 0.789; p < 0.001) and z (r = 0.856; p < 0.001) directions by linear regression analysis. Systematic deviations within each group were <1 mm; however, random and systematic errors were similar in the x and y directions but larger in the z direction.
CONCLUSION: Our study demonstrated that CBCT-FM was not superior to CBCT-P for image-guided radiotherapy in prostate cancer patients.

Entities:  

Keywords:  Cone-beam CT; Fiducial marker; Image-guided radiotherapy; Prostate cancer; Setup errors

Mesh:

Year:  2016        PMID: 27730453     DOI: 10.1007/s11604-016-0590-y

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  36 in total

1.  Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.

Authors:  Carlos Vargas; Di Yan; Larry L Kestin; Daniel Krauss; David M Lockman; Donald S Brabbins; Alvaro A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

3.  Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.

Authors:  Stephanie T H Peeters; Joos V Lebesque; Wilma D Heemsbergen; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Peter C M Koper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-18       Impact factor: 7.038

4.  Comparing methods of measurement: why plotting difference against standard method is misleading.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

5.  Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.

Authors:  Patrick Berkovic; Gert De Meerleer; Louke Delrue; Bieke Lambert; Valérie Fonteyne; Nicolaas Lumen; Karel Decaestecker; Geert Villeirs; Philippe Vuye; Piet Ost
Journal:  Clin Genitourin Cancer       Date:  2012-09-24       Impact factor: 2.872

6.  Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy.

Authors:  S Gill; J Li; J Thomas; M Bressel; K Thursky; C Styles; K H Tai; G M Duchesne; F Foroudi
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

7.  Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation.

Authors:  Homan Dehnad; Aart J Nederveen; Uulke A van der Heide; R Jeroen A van Moorselaar; Pieter Hofman; Jan J W Lagendijk
Journal:  Radiother Oncol       Date:  2003-06       Impact factor: 6.280

8.  Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer.

Authors:  Abrahim Al-Mamgani; Wim L J van Putten; Wilma D Heemsbergen; Geert J L H van Leenders; Annerie Slot; Michel F H Dielwart; Luca Incrocci; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-19       Impact factor: 7.038

9.  A study on adaptive IMRT treatment planning using kV cone-beam CT.

Authors:  George X Ding; Dennis M Duggan; Charles W Coffey; Matthew Deeley; Dennis E Hallahan; Anthony Cmelak; Arnold Malcolm
Journal:  Radiother Oncol       Date:  2007-08-20       Impact factor: 6.280

Review 10.  Intensity-modulated radiation therapy: supportive data for prostate cancer.

Authors:  Oren Cahlon; Margie Hunt; Michael J Zelefsky
Journal:  Semin Radiat Oncol       Date:  2008-01       Impact factor: 5.934

View more
  2 in total

1.  In Regard to Shee et al.

Authors:  Sukran Senyurek; Duygu Sezen; Yasemin Bolukbasi
Journal:  Adv Radiat Oncol       Date:  2022-09-16

Review 2.  Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins.

Authors:  Marcus Bauer; Christoforos Vaxevanis; Nadine Heimer; Haifa Kathrin Al-Ali; Nadja Jaekel; Michael Bachmann; Claudia Wickenhauser; Barbara Seliger
Journal:  Int J Mol Sci       Date:  2020-09-27       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.